print_label | resize_label

FASLODEX licenced dose

FASLODEX is unique amongst contemporary hormonal therapies for breast cancer in that it is administered as a monthly intramuscular injection (into the gluteus maximus muscle) rather than as an oral tablet regimen.1,2

The approved clinical dosage of FASLODEX is 500 mg in the EU. FASLODEX is supplied as two 250 mg doses in 5 mL (50 mg/mL) sterile solution, prefilled, ready-to-use syringe fitted with a BD SafetyGlideTM needle. Two 5 mL syringes need to be administered into the dorsogluteal site of each buttock.2

FASLODEX (fulvestrant) injection: monthly intramuscular injection

  • FASLODEX (fulvestrant) is administered as monthly intramuscular (IM) injections into the buttocks1
  • FASLODEX is provided as two single doses of 250 mg in a 5 mL (50 mg/mL) solution and is supplied ready to use in a sterile, prefilled syringe fitted with a BD SafetyGlideTM needle2,3
  • For the 500 mg dose, 2 injections need to be administered2

The FASLODEX injection should be administered into the gluteus maximus muscle under pressure and the injection should take approximately 1-2 minutes.2

Click on the image to see a larger view

Aiding FASLODEX IM administration

To aid in making administration of the FASLODEX injection as simple and as comfortable as possible for both patient and administrator, the following guidance and tips may be useful:

  • Administer slowly (approximately 1-2 minutes), as FASLODEX is a viscous liquid.3 It is advisable to let the patient know this in advance
  • No calculation of body surface is required
  • FASLODEX must be refrigerated at 2°C to 8°C. Do not freeze. For patient comfort, FASLODEX should be brought to room temperature before administration by2:
    • Removing from the refrigerator for a short period of time until room temperature is reached, or
    • Rolling the prefilled syringe between the palms of the hands for a short period of time prior to administration
  • The Z-track technique can be used as an option but is not a requirement.3

Positioning the patient

Make sure that the patient is comfortable before you begin. The patient either can lie in a prone or semi-prone position or can stand while leaning forward.3

The use of the semi-prone position has the advantage that any surplus adipose tissue falls naturally downward, allowing clear identification of the injection site.3

FASLODEX fulvestrant Injection semi-prone position

The use of the standing and leaning position might be more comfortable for those patients who have limited movement or bone pain.3

FASLODEX fulvestrant Injection standing position

FASLODEX 500 mg dosing schedule

Click on the image to see a larger view

Derived from the FASLODEX Summary of Product Characteristics.2

Precautions related to FASLODEX IM administration

Because the FASLODEX injection is administered intramuscularly, it should be used with caution in patients with bleeding diatheses, with thrombocytopaenia or on anti-coagulant therapy.2

References

  1. Ciruelos E et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast 2014; 23(3): 201–208.
  2. FASLODEX Summary of Product Characteristics. Document available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000540/WC500021174.pdf. Accessed 12 August 2015.